학술논문

The combination of EGFR-TKIs and anlotinib as a first-line therapy for EGFR-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2021, 39 15, 2p. Supplement: S
Subject
Language
English
ISSN
15277755